For instance, in the case of glioblastoma multiform expressing the human poliovirus receptor CD155, administration of an oncolytic recombinant poliovirus (PVS-RIPO) through intrathecal delivery demonstrated a significant elevation in the median survival time among transgenic mice (73). This evidence concerns the gene PVR and glioblastoma.